georgeclerk
- Citing recruitment problems, Pfizer has ended a phase 2 trial of maplirpacept, a candidate targeting CD47 that the drug giant obtained in August 2021 as part of its $2.26B acquisition of Trillium Therapeutics.
- “The trial terminated due to the inability to recruit the planned number of subjects,” according to an update on the trial’s page on ClinicalTrial.gov. “The decision was not based on any safety and/or efficacy concerns.”
- The page indicated that at the time the trial was cancelled, just six participants were enrolled.
- The trial was testing maplirpacept in combination with Monjuvi (tafasitamab) and Revlimid (lenalidomide) for diffuse large B-cell lymphoma.
- Maplirpacept is still in phase 1 for multiple myeloma.
More on Pfizer
- Pfizer Could Be The Turnaround Story In The Pharmaceutical Space
- Don’t Sleep On Pfizer: The Turnaround Is Just Getting Started
- Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn’t Rule It Out
- COVID shot makers in focus as RFK Jr. revamps vaccine injury compensation program
- WHO report says COVID-19 likely originated in transfer from wild animals to humans